CHRNA1 promotes the pathogenesis of primary focal hyperhidrosis

Lin, Jianbo; Kang, Mingqiang; Huang, Liping; Zhuo, Yi; Xu, Li; Lai, Fan-Cai

doi:10.1016/j.mcn.2021.103598

Cited by 10 publications

(19 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[3] In the Cox proportional hazard model for ineffective treatment show that higher risk in patients with family history than without, which the reason may from variants or mutations located outside the coding regions. [4,15] This study has several limitations. First, an observational study to evaluating the clinical e cacy of RFA and VATS are potentially subjected to selection bias.…”

Section: Discussionmentioning

confidence: 95%

“…However, sympathectomy is the last resort of treatment when conservative treatments are a failure or intolerable,[18] which treatment history did not affect the clinical outcome of sympathectomy. [3,4] Second, the proposed different follow-up times were observed for RFA or VATS treatment effect with HDSS and QOL needs to be independently assessed. [33] In this context, it is essential to note that the endpoint assessment for treatment of clinical e cacy for long-term outcomes might need more concerned.…”

Section: Discussionmentioning

confidence: 99%

“…A pathogenesis study of PHH shows that the cholinergic receptor nicotinic alpha 1 subunit and activin a receptor type 1 maybe involvement of the pathogenesis of primary hyperhidrosis. [4,5] Another genomewide analysis of families with PHH shows that variants or mutations located outside the coding regions might be involved in the molecular pathogenesis of PHH. [3] In the Cox proportional hazard model for ineffective treatment show that higher risk in patients with family history than without, which the reason may from variants or mutations located outside the coding regions.…”

Section: Discussionmentioning

confidence: 99%

“…[1][2][3] which the cholinergic receptor nicotinic alpha 1 subunit and activin a receptor type 1 maybe involvement of the pathogenesis of primary hyperhidrosis. [4,5] The main involved symptom parts include hand, axilla, craniofacial region, and feet. [6,7] Hyperhidrosis causes great troubles to patients' social life and work, and even depression in severe cases; severely affected patients have skin maceration and secondary microbial infections.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Efficacy and Safety of Radiofrequency Ablation Versus Video-assisted Thoracoscopic Sympathectomy in Palmar Hyperhidrosis: A Multicenter Cohort Study

Zhong¹,

Zhu²,

Li³

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: Radiofrequency ablation (RFA) was adopted as an alternative to surgical options for sympathectomy in patients with palmar hyperhidrosis (PHH), but the RFA comparative efficacy of treatments by video-assisted thoracoscopic sympathectomy (VATS) on long-term remains uncertain.Methods: We recruited patients aged ≥14 years with diagnosed PHH from 14 centers in China. The treatment options of RFA or VATS were recruited in patient with informed consent. The primary outcome was the clinical efficacy in 1-year. Propensity scoring and multivariable models respectively were used to evaluate the clinical efficacy and inefficacy risk of treatment options.Results: A total of 807 patients were enrolled, 351 patients underwent RFA, and 456 were VATS. After propensity score matching, the rate of complete remission was lower in RFA than in VATS (79.2% [247/312] versus 91.3% [285/312], 95% confidence intervals [CI] 0.21 to 0.57, p<0.001). However, the rate of palmar dryness (95% CI 0.38 to 0.92, p=0.020), of postoperative pain (95% CI 0.13 to 0.33, p<0.001), and of surgical-related complication (95% CI 0.19 to 0.85, p=0.020) is lower in RFA group than in VATS group, and radiofrequency ablation group of skin temperature rise is more common (95% CI 1.84 to 3.58, p<0.001).Conclusion: Performing RFA had a lower success rate than VATS for the complete remission of palmar hyperhidrosis. However, RFA may be better reasonable treatment option for palmar hyperhidrosis before surgical sympathectomy, because it more possibly accepted and generalized due to lower symptomatic burden and costs than surgical sympathectomy in patients.Trial RegistrationChiCTR2000039576, URL: http://www.chictr.org.cn/index.aspx

show abstract

Section: Discussionmentioning

confidence: 95%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Efficacy and Safety of Radiofrequency Ablation Versus Video-assisted Thoracoscopic Sympathectomy in Palmar Hyperhidrosis: A Multicenter Cohort Study

Zhong¹,

Zhu²,

Li³

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…Studies have shown that CHRNA1 is the cholinergic receptor nicotinic alpha1 subunit, which is involved in the binding and gating of the Ach neurotransmitter 12 . If PFH model mice are induced and injected with siRNA of Chrna1 gene, it can be seen that the siRNA can alleviate the symptoms of PFH and reduce the content of PFH biomarker molecules 11 . Our previous study suggested that the increased expression of Chrna1 is an important cause of excessive sweat secretion, and the use of small molecules to block the activity of Chrna1 may be an effective method for the treatment of PFH.…”

Section: Introductionmentioning

confidence: 99%

Antagonist of Chrna1 prevents the pathogenesis of primary focal hyperhidrosis

Lin

et al. 2022

Ann Clin Transl Neurol

Self Cite

View full text Add to dashboard Cite

Background: Primary focal hyperhidrosis (PFH) is an autonomic neurological disease in which exocrine glands are oversecreted due to autonomic dysfunction of the sympathetic nervous system. Chrna1 promotes the pathogenesis of PFH. We aimed to check if downregulating of Chrna1 by cisatracurium could alleviate the symptoms of PFH. Methods: The effect of cisatracurium in a hyperhidrosis mice model induced by pilocarpine hydrochloride was monitored for sweat gland secretion, and ultrastructural sweat secretory granules in sweat glands were analyzed. Meanwhile, markers of hyperhidrosis were checked, and release of Bdnf and Nrg1 from sympathetic ganglia axon was tested. Furthermore, the mechanism of cisatracurium function was evaluated in vitro using HEK293 expressing Chrna1. Finally, the effect of cisatracurium was determined in the hyperhidrosis mice model with overexpression or downregulation of Chrna1. Results: In hyperhidrosis mice, pretreatment with cisatracurium effectively inhibited sweat secretion, along with fewer particle secretion in sweat glands. The molecular markers of hyperhidrosis (Aqp5 and Cacna1c) were inhibited by cisatracurium, acetylcholine (Ach) level in serum was found decreased. Neurotrophic factors (Bdnf and Nrg1) secreted by sympathetic axon activation were also inhibited. At last, it was confirmed that cisatracurium could not alter the gene or protein expression level of Chrna1, but could block the ion channel. Overexpression of Chrna1 abolished the effect of cisatracurium on hyperhidrosis, while cisatracurium could not function more in siChrna1treated mice. Conclusion: Our results suggested that pretreatment of cisatracurium could alleviate hyperhidrosis in mice, probably through blocking the ion channel function of Chrna1.

show abstract

Aquaporins in Glandular Secretion

Calamita

Delporte

2023

Advances in Experimental Medicine and Biology

View full text Add to dashboard Cite

Exocrine and endocrine glands deliver their secretory product, respectively, at the surface of the target organs or within the bloodstream. The release of their products has been shown to rely on secretory mechanisms often involving aquaporins (AQPs). This chapter will provide insight into the role of AQPs in secretory glands located within the gastrointestinal tract, including salivary glands, gastric glands, duodenal Brunner's glands, liver, gallbladder, intestinal goblets cells, and pancreas, as well and in other parts of the body, including airway submucosal glands, lacrimal glands, mammary glands, and eccrine sweat glands. The involvement of AQPs in both physiological and pathophysiological conditions will also be highlighted.

show abstract

CHRNA1 promotes the pathogenesis of primary focal hyperhidrosis

Cited by 10 publications

References 16 publications

Efficacy and Safety of Radiofrequency Ablation Versus Video-assisted Thoracoscopic Sympathectomy in Palmar Hyperhidrosis: A Multicenter Cohort Study

Efficacy and Safety of Radiofrequency Ablation Versus Video-assisted Thoracoscopic Sympathectomy in Palmar Hyperhidrosis: A Multicenter Cohort Study

Antagonist of Chrna1 prevents the pathogenesis of primary focal hyperhidrosis

Aquaporins in Glandular Secretion

Contact Info

Product

Resources

About